A5073687210- Immunotherapy and Immune Responses
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Eosinophilic Disorders and Syndromes
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- RNA Interference and Gene Delivery
- COVID-19 Clinical Research Studies
- Immune cells in cancer
- T-cell and B-cell Immunology
- Long-Term Effects of COVID-19
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- vaccines and immunoinformatics approaches
- SARS-CoV-2 and COVID-19 Research
- Advanced biosensing and bioanalysis techniques
- Lung Cancer Treatments and Mutations
- DNA and Nucleic Acid Chemistry
- Immune Response and Inflammation
- Nuclear Physics and Applications
- Renal and related cancers
University Hospital Bonn
2016-2025
University of Bonn
2010-2024
Tyrolean Cancer Research Institute
2021
Society of Interventional Radiology
2021
Center for Rheumatology
2014-2016
Heinrich Heine University Düsseldorf
2016
Düsseldorf University Hospital
2016
Novartis (Germany)
2016
Bristol-Myers Squibb (Germany)
2016
Universitätsmedizin Greifswald
2009
The aim of this phase I/II nonrandomized trial was to assess feasibility, safety as well immunological and clinical responses a mRNA-based vaccination in patients with stage IV renal cell cancer using granulocyte-macrophage colony stimulating factor (GM-CSF) adjuvant. Intradermal injections vitro transcribed naked mRNA, which generated plasmids coding for the tumor-associated antigens mucin 1(MUC1), carcinoembryonic (CEA), human epidermal growth receptor 2 (Her-2/neu), telomerase, survivin,...
Ruxolitinib is a small-molecule inhibitor of the JAK kinases, which has been approved for treatment myelofibrosis, rare myeloproliferative neoplasm (MPN), but clinical trials are also being conducted in inflammatory-driven solid tumors. Increased infection rates have reported ruxolitinib-treated patients, and natural killer (NK) cells immune effector known to eliminate both virus-infected malignant cells. On this basis, we sought compare effects inhibition on human NK cohort 28 MPN patients...
Summary Ruxolitinib ( INCB 018424) is the first JAK 1/ 2 inhibitor approved for treatment of myelofibrosis. / STAT ‐signalling known to be involved in regulation CD 4 + T cells, which critically orchestrate inflammatory responses. To better understand how ruxolitinib modulates cell responses, we undertook an in‐depth analysis function upon exposure. We observed a decrease total 3 cells after weeks patients with myeloproliferative neoplasms. Moreover, found that number regulatory (Tregs),...
A 79-year-old male was hospitalized due to fatigue, shortness of breath, and recurrent syncopes.He denied symptoms fever or pain.He had a previous history asthma.No cardiovascular disease reported, cardiac check-ups were unremarkable (last described left ventricular ejection fraction 65%).Initial physical examination in the emergency department revealed heart rate 75 bpm, blood pressure 101/64 mm Hg, body temperature 35.6°C, oxygen saturation 94%, moderate wheezing on auscultation.On initial...
Biomarkers for predicting response to anti-programmed death-1 (PD-1) immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) remain demand. Since anti-tumor activation is a process, early dynamic changes of the acute-phase reactant C reactive protein (CRP) may serve as predictive on-treatment biomarker. In retrospective (N=105) and prospective (N=108) ICB-treated NSCLC cohort, CRP kinetics were stratified after start immunotherapy until weeks 4, 6, 12 follows: an doubling...
Prolonged shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been observed in immunocompromised hosts. Early monotherapy with direct-acting antivirals or monoclonal antibodies, as recommended by the international guidelines, does not prevent this certainty. Dual therapies may therefore have a synergistic effect.
Background Myocardial injury and inflammation at cardiac MRI in patients with COVID-19 have been described recent publications. Concurrently, a chronic syndrome (CCS) after SARS-CoV-2 infection has observed manifests symptoms such as fatigue exertional dyspnea. Purpose To explore the relationship between CCS myocardial an underlying cause of persistent complaints previously healthy individuals. Materials Methods In this prospective study from January 2021 to April 2021, participants without...
Background Immune checkpoint inhibitors (ICIs) for cancer treatment are associated with a spectrum of immune-related adverse events, including ICI-induced myocarditis; however, the extent subclinical acute cardiac effects related to ICI is unclear. Purpose To explore injury and inflammation therapy that can be detected use MRI. Materials Methods In this prospective study from November 2019 April 2021, oncologic participants, without known underlying structural heart disease or symptoms,...
A prerequisite for the development of vaccination strategies is identification and characterization relevant tumor-associated antigen. Using microarray reverse transcription-PCR analysis, we found matrix metalloproteinase (MMP)-7 to be extensively up-regulated in renal cell carcinomas expressed a broad variety malignant cells. MMP-7 can promote cancer invasion angiogenesis by proteolytic cleavage extracellular basement membrane proteins, thus making it promising target context...
Renal cell carcinoma (RCC) is an immunogenic tumor for which immunotherapeutic approaches could be associated with clinically relevant responses. It was recently shown, that induction of T-cell responses against multiple tumor-associated antigen (TAA) epitopes results in prolonged overall survival RCC patients. In 2003-2005, we performed a phase I/II trial testing mRNA-based vaccine formulation consisting mixture vitro transcribed RNA coding six different TAAs (MUC1, CEA, Her2/neu,...
Management of patients with metastatic squamous cell skin cancer, refractory to initial therapy standard chemotherapy and radiation protocols, remains difficult poor overall prognosis limited therapeutic options. Recently, promising response rates nivolumab, a programmed death receptor-1-blocking antibody, in cancer the head neck have been demonstrated. Considering similar histological patterns neck, we assumed that nivolumab could also be effective our skin. So far, there no clinical data...
S ARS-CoV-2 infection, and the resulting COVID-19, has become a worldwide pandemic.Although primarily affecting respiratory system, COVID-19-associated myocardial injury is common can occur directly due to viral infection or indirectly systemic inflammation, endothelial activation, and/or microvascular thrombosis (1,2).Besides infarction, also be result of inflammation (2).However, current information about associated mainly limited case reports series (3).As cardiac MRI important for...
The intersection of coronavirus (COVID-19) and heart disease has emerged as a critical nexus in the landscape global health. Individuals with face elevated risks when infected Severe Acute Respiratory-Syndrome Coronavirus-type-2 (SARS-CoV-2) leading to COVID-19. virus can directly affect heart, resulting myocarditis, arrhythmias, failure, even individuals without prior medical cardiac history. Therefore, tools identifying patients infestation predicting severity are utmost importance. This...
The investigation of Graft-versus-Host disease after allogeneic stem cell transplantation heavily relies on the use experimental animal models and total body irradiation (TBI) as a conditioning regimen. However, 137Cs is gradually being replaced main source radiation due to safety concerns transfer established protocols x-ray irradiators has proven difficult. Here, we describe establishment an x-ray-based protocol in mouse model for acute GvHD (C57BL6 → BALB/c). Our data show that commonly...